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RIASSUNTO 
 
La leucemia linfoblastica acuta a cellule T (T-ALL) è una malattia eterogenea 
caratterizzata da diverse alterazioni genetiche e caratteristiche cliniche, sia in età 
pediatrica che adulta. Un ruolo importante in questo tipo di neoplasia è ricoperto 
dal pathway di Notch, meccanismo evolutivamente conservato coinvolto in 
numerosi processi biologici tra cui il differenziamento dei linfociti T; difatti in 
circa il 50-55% dei pazienti affetti da T-ALL si riscontra una mutazione attivante 
nel gene NOTCH1 o a carico di FBW7. Dal momento che solo il 70-80% dei 
bambini e il 40% degli adulti affetti da questo tipo di leucemia riesce a 
raggiungere la remissione a lungo termine, e’ necessario sviluppare ed adottare 
nuove strategie terapeutiche per poter curare anche i pazienti refrattari alle terapie 
convenzionali. A questo scopo abbiamo analizzato gli effetti biologici e 
terapeutici di un anticorpo neutralizzante specifico per il recettore Notch1 umano, 
avvalendoci di un modello di xenotrapianto di T-ALL. Tale modello è stato 
generato nel nostro laboratorio utilizzando campioni ottenuti da pazienti pediatrici 
con caratteristiche cliniche differenti e presentanti diverso stato mutazionale di 
NOTCH1/FBW7. Il trattamento con anti-Notch1 si è rivelato efficace nel 
contrastare la crescita della leucemia dei campioni con mutazione di 
NOTCH1/FBW7, compresi campioni derivati da pazienti in ricaduta o poco 
responsivi alle terapie convenzionali. In seguito alla somministrazione di anti-
Notch1, in questi xenotrapianti abbiamo osservato un aumento dei livelli di 
apoptosi, una riduzione della proliferazione, un effetto inibitorio molto marcato 
sui profili trascrizionali dei geni target di Notch e inoltre una modulazione del 
metabolismo cellulare delle cellule leucemiche. Gli esperimenti di inoculo seriale 
indicano che la terapia con anti-Notch1 può compromettere la capacità di dare 
origine a leucemia delle cellule di T-ALL residue dopo il trattamento. Inoltre un 
esperimento preliminare ha rivelato che la somministrazione continua 
dell’anticorpo anti-Notch1 può causare l’insorgenza di fenomeni di resistenza alla 
terapia. Infine abbiamo dimostrato che la combinazione di anti-Notch1 e 
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desametasone, un farmaco comunemente utilizzato nel trattamento delle T-ALL, 
può ulteriormente migliorare l’efficacia terapeutica.  
Nel complesso, i nostri risultati indicano che la presenza di mutazioni in 
NOTCH1/FBW7 identifica dei candidati che potrebbero beneficiare di una terapia 
mirata contro Notch1 e sottolinea la potenzialità del valutare l’espressione dei 
geni target di Notch e del CD7 come marcatori predittivi della risposta terapeutica 
all’anti-Notch1. 
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ABSTRACT 
 
T-cell acute lymphoblastic leukemia (T-ALL) is an heterogeneous disease, 
characterized by several genetic alterations and polymorphic clinical features both 
in children and adults. The Notch pathway, an evolutionary conserved pathway 
involved in many biological processes including T cell differentiation, has been 
implicated in the pathogenesis of this disease. Notably, about 50-55% of T-ALL 
samples show increased Notch1 activity, due to mutations in NOTCH1 or FBW7 
genes. Among T-ALL patients, only 70-80% of children and 40% of adults reach 
long-term remission, therefore new therapeutic approaches are required. Here, we 
investigated the biologic and therapeutic effects of a human Notch1-specific 
neutralizing antibody in xenograft models of pediatric T-ALL, obtained from 
patients with different clinical features and NOTCH1/FBW7 mutational status. We 
demonstrated that anti-Notch1 treatment greatly delayed engraftment of T-ALL 
cells bearing NOTCH1/FBW7 mutations, including samples derived from relapsed 
and clinically difficult-to-treat patients. In these xenografts we observed increased 
levels of apoptosis, decreased proliferation of leukemic cells and a marked 
inhibitory effects on Notch transcriptional profile. Moreover, modulation of T-
ALL cells metabolism was detected following anti-Notch1 therapy. Serial 
transplantation experiments suggested that anti-Notch1 therapy could compromise 
leukemia initiating cell functions and a preliminary experiment showed that 
resistance may arise in a regimen of continuous administration of anti-Notch1 
mAb. Finally, we demonstrated that combination of anti-Notch1 and 
dexamethasone – a leading drug in T-ALL treatment - could further improve 
therapeutic effect.  
Altogether these results indicate that NOTCH1/FBW7 mutations identify suitable 
candidates for Notch targeted therapy and highlight the potential of Notch target 
genes and CD7 expression as candidate predictive markers of response to anti-
Notch1 therapy. 
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1. INTRODUCTION 
 
1.1 T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
 
1.1.1 Molecular pathogenesis of T-ALL  
T-cell acute lymphoblastic leukemia (T-ALL) is an hematologic disease induced 
by the transformation of T-cell progenitors. T-ALL are approximately 15% and 
25% of the newly diagnosed cases of ALL in children and in adults, respectively. 
Compared to the more common B-cell-lineage ALL, T-ALL is associated with 
more unfavorable clinical features, such as a high white-blood-cell count, bulky 
adenopathy, involvement of the central nervous system and is linked with a poor 
prognosis. The onset of T-ALL is due to transformation events that arise in crucial 
steps of intrathymic T-cell differentiation and expression of certain oncogenes has 
been closely linked to developmental arrest at particular stages of normal 
thymocytes development (Aifantis et al., 2008). Each stage of maturation is 
accompanied by a distinct pattern of intracellular and cell surface markers so the 
immunophenotype analysis provides the basis for the commonly used EGIL 
(European Group for the Immunological Characterization of Leukemias) 
classification system. Also T-cell receptor based classification system reflect 
stages of physiological development but it is less widely used in the clinical 
practice (Fielding et al., 2012).  
Current knowledge of T-ALL biology entails five key issues: 
• Chromosomal aberrations: approximately 50% of T-ALL cases have 
chromosome aberrations but T-ALL cytogenetics is not well understood as 
occurs in B-ALL, where cytogenetic analysis is used to draw therapeutic 
decisions. Chromosomal aberrations in T-ALL can be divided into three 
categories. The first includes rearrangements of proto-oncogenes to TCR 
gene locus, leading to overexpression of rearranged proto-oncogenes (such 
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as LMO1, LMO2, TAL1). The second includes rearrangements of 
transcription factors-coding genes, resulting in the production of aberrant 
fusion transcription factors (for example STIL-TAL1, TLX3-BCL11B). The 
third concerns rearrangements of the MLL gene to different translocation 
partner genes. Some of the transcription factors involved in 
rearrangements are normally expressed in non-malignant thymocytes and 
are essential regulators of T-cell development, whereas others are 
ectopically expressed by transformed cells in T-ALL and not expressed in 
normal thymus. These chromosomal translocations cause aberrant patterns 
of gene expression in T-cells and lead to abnormal cell-cycle control, 
proliferation and differentiation (Aifantis et al., 2008; Kraszewska et al., 
2012b). 
• Gene expression profiles: most T-ALL patients show pathological gene 
expression even in the absence of chromosome aberrations. It was 
demonstrated that T-ALL patients cluster into several groups characterized 
by differential gene expression patterns (Ferrando et al., 2002). Patients 
could be divided into four groups based on the aberrant, subtype-specific, 
expression of TLX1, LYL1, TAL1/LMO2 and TLX3 oncogenes. TLX1 
encodes a transcription factor belonging to the homeobox family with a 
role in T-ALL pathogenesis highlighted by different studies. LYL1 and 
TAL1 are two related basic helix-loop-helix genes expressed in 
hematopoietic and endothelial lineages. TAL1 is essential for 
hematopoietic and vascular development whereas LYL1 seems to act 
mainly in adult neovasculatization (Pirot et al., 2010). LMO2 codes for a 
transactivating protein that has activity in erythropoiesis and 
leukemogenesis. TAL1 and LMO2 are found simultaneously overexpressed 
in the same samples so these two genes characterize one T-ALL subtype. 
Finally, TLX3 encodes a homeobox transcription factor found to be 
involved in T-ALL pathogenesis, whether or not a chromosome 
translocation was detected (Kraszewska et al., 2012b). Overexpression of 
HOXA genes was further proposed as a factor defining a separate T-ALL 
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subtype (Dik et al., 2005). The number of T-ALL subtypes defined by 
gene expression profiling data is quite limited, considering that 50% of T-
ALL patients carry chromosomal aberrations. A possible explanation is 
that various molecular aberrations can lead to overexpression of the same 
oncogenes. Recently a novel T-ALL subtype, characterized by a distinct 
gene expression profile, expression of specific cell surface antigens and 
increased number of genetic alterations, has been identified. This subtype 
is named early T-cell precursor leukemia (ETP-ALL), arises from stem 
cell-like precursors of thymocytes and is associated with a very poor 
prognosis (Coustan-Smith et al., 2009). In addition to genome wide gene 
expression analysis, recent studies have described T-ALL-specific miRNA 
expression profiles (Mavrakis et al., 2011). 
• Gene mutations: additional genetic abnormalities observed in T-ALL 
include mutations in NOTCH1 and FBW7 genes - which will be described 
later – and the new candidate genes involved in T-ALL pathogenesis 
FLT3, BCL11B, PTPN2, PHF6, NRAS, WT1, CDKN2A and IL7R. The 
discovery of these genes has contributed to the knowledge about T-ALL 
biology but none of them have proved so far to have prognostic value. 
• Immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements, 
including Ig/TCR- based monitoring of minimal residual disease (MRD): 
during lymphocyte maturation, rearrangement of the TCR loci occurs, in 
order to generate the T cell diversity required for an appropriate immune 
response. This process is mediated by a recombinase enzyme complex 
which randomly joins unique V, D, J gene segments together to form 
various combinations. Rearrangement diversity is further increased by 
small deletions and insertions of nucleotide mediated by terminal 
deoxynucleotidyl transferase (TDT). Every lymphocyte clone, including 
leukemic clones, carry unique Ig/TCR gene rearrangements so the study of 
rearrangement pattern might be used for immunogenetic characteristics of 
T-ALL, as indicators of clonality in diagnosis of lymphoproliferative 
disorders and for monitoring the MRD. The recombination events that 
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occur during T cell development require that the thymocyte DNA be 
inclined to breakage and rejoining, causing lymphocyte-specific genetic 
instability and so supporting the process of malignant transformation. In 
normal T cells only TCR rearrangements occur, however in 20% of T-ALL 
cases there is also an incomplete immunoglobulin heavy chain 
rearrangement, caused by a high activity of recombinase in leukemic cells 
and abnormal Ig/TCR locus accessibility due to uncontrolled cell 
proliferation. Ig/TCR gene rearrangements reflect the stage of T-cell 
precursor that undergoes leukemic transformation. Ig/TCR gene 
rearrangements are investigated for clinical reasons but they are not related 
to the oncogenic process. The level of MRD has revealed to be the most 
reliable prognostic marker in T-ALL, as explained it the last section. 
• DNA methylation: the few studies existing so far on methylation status in 
T-ALL demonstrate that DNA methylation of particular genes, such as 
PTEN, is different between T-ALL patients, healthy children and normal 
thymic cell populations. However, these results need to be confirmed in 
large prospective studies (Roman-Gomez et al., 2005) (Kraszewska et al., 
2012a). 
Gene mutations, chromosome rearrangements and oncogene overexpression can 
be linked as mechanisms leading to a disruption of cellular pathways controlling 
lymphocyte differentiation and proliferation (Kraszewska et al., 2012b). 
 
1.1.2 Overview of T-cell development  
Initiation of lymphoid commitment is not fully understood, with several 
haematopoietic-cell populations being proposed as lymphocytes progenitors. 
Nevertheless, the cells that are committed to become T-cells exit the bone marrow 
and migrate through the blood to the thymus in a chemotactic process that is 
controlled by adhesion molecules. The microenvironment in the thymus allows 
development of multi-potential progenitors and correct maturation of T-cells. The 
first precursors that migrate to the thymus are early T-cell-lineage progenitors 
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(ETPs) or double negative 1 (DN1) cells, phenotypically belonging to a CD3-
CD4-/low CD8-CD25-CD44hiKIT+ fraction. In the T lineage commitment, they first 
down-regulate KIT expression, thus becoming CD4-CD8-CD25+CD44+ DN2 
cells, then CD44, becoming DN3 cells CD4-CD8-CD25+CD44-, and finally CD25, 
becoming DN4 cells CD4-CD8-CD25-CD44-. During these events, T-cells 
progenitors remain in intimate contact with thymic epithelial stromal cells. This 
contact is essential because stromal cells express Notch ligands and produce 
growth factors and morphogenes that control T-progenitors development. Upon 
pre-T-cell receptor (pre-TCR) engagement, thymocytes differentiate into double 
positive (DP, CD4+CD8+) cells, that enter the processes of positive and negative 
selection. Selected T-cells exit the thymus as mature single positive (SP) CD4+ or 
CD8+ cells (Aifantis et al., 2008) (Fig. 1). Different pathways contribute to drive 
T cell development, in particular Notch signaling has a critical role as explained in 
the next section. 
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Figure 1: Stages of haematopoiesis and T-cell development: Outline of the T-cell development, 
from haematopoietic stem cells (HSCs) to multipotent progenitors (MPPs) and to common 
lymphoid progenitors (CLPs). These subsets migrate from the bone marrow to the thymus as early 
T-cell-lineage progenitors (ETPs) and commit to the T-cell lineage, progressing through the 
double negative stages DN2, DN3, DN4. When pre-TCR-selected cells reach the double positive 
(DP) stage, they are subjected to the positive and negative selection. Selected cells exit the thymus 
as single positive (SP) CD4+ or CD8+ T-cells. Oncogenes, including Notch1, that are known to be 
associated with T-ALL are reported (Aifantis et al., 2008).  
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1.2 NOTCH 
 
1.2.1 Notch signaling 
Notch is a key regulator of different cellular processes, such as differentiation, 
proliferation, apoptosis, adhesion and spatial development. Mammals have four 
Notch receptors (Notch1-Notch4) and five Notch ligands (JAG1, JAG2, DLL1, 
DLL3, DLL4), all of which are single-pass transmembrane proteins so Notch 
pathway functions as a mediator of short-range cell-cell communication. Notch 
proteins are first synthesized as single-pass transmembrane glycoproteins of 300-
350 kDa, which are later proteolytically processed in the Golgi by a furin-like 
convertase at a site called S1. This processing generates two noncovalently 
associated subunits, the extracellular Notch (NEC) and the transmembrane Notch 
(NTM), which constitute the mature heterodimeric form of the receptor present at 
the cell surface. The extracellular domain contains a variable number (29-36) of 
N-terminal epidermal growth factor (EGF)-like repeats that include the ligands-
binding region. Beyond the EGF-like repeats there is a negative regulatory region 
(NRR) containing three LNR modules (LIN12/Notch repeats), which contribute to 
avoid premature activation of Notch receptors. The transmembrane subunit 
contains a short extracellular region, a transmembrane segment and an 
intracellular region (ICN), which is further divided in a RAM (RBPJ-associated 
module) domain, six/seven ankyrin (ANK) repeats flanked by two nuclear 
localization signals (NLSs), a transactivation domain (TAD) and a PEST region. 
The ANK and RAM domains participate to the binding of the transcription factor 
RBPJ or CSL while the ANK domain is essential for recruitment of co-activators 
and transactivation. The NLSs sequences allow the nuclear localization of the 
intracellular region, TAD is the transactivation domain and the PEST sequence 
(proline-glutamic acid-serine-threonine-rich domain) is essential for protein 
stability and for its proteasome-mediated degradation. Ligands are members of the 
DSL (Delta, Serrate and LAG2) family, they are transmembrane proteins 
containing a transmembrane domain, a small cytoplasmic tail, variable numbers of 
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EGF-like repeats and a DSL domain essential for binding to the EGF-like domain 
in the Notch extracellular subunit (fig. 2) (Kopan and Ilagan, 2009; Sanchez-
Irizarry et al., 2004).  
 
 
Figure 2. Molecular components of the Notch pathway. The five ligands share structural 
homology including a DSL domain, a variable number (6-18) of EGF-like repeats, a 
transmembrane domain and a small cytoplasmic tail. JAG1 and JAG2 have also a cysteine-rich 
domain. The four receptors also share structural homology, with EGF-like repeats, LNR domain, a 
juxtamembrane region with specific proteinase cleavage sites, a transmembrane region including a 
cleavage site for γ-secretase, and a cytoplasmic region that contains several functional domains 
(RAM, ANK, NLS,TAD and PEST described in the text). TAD domain is weaker in NOTCH2 
compared to NOTCH1 while it is absent in NOTCH3 and NOTCH4 [DLL: Delta-like ligand; 
JAG: Jagged; DSL: Delta, Serrate and LAG2; CR: cysteine-rich domain]. (Thurston et al., 2007). 
 
Canonical Notch activation is initiated when receptors engage ligands expressed 
on a neighboring cell. Ligand binding to repeats within the EGF-like domain of 
the receptor causes two sequential proteolytic events called S2 and S3 cleavages, 
mediated by ADAM (a disintegrin and metalloproteinase family) or TACE (TNF-
α converting enzyme) and by γ-secretase, respectively. Ligand binding causes the 
exposure of the S2 cleavage site otherwise buried within the NRR in the “off-
state” of the receptor. The two consecutive cleavages produce the Notch 
intracellular domain (ICN) which is released from the plasma membrane and 
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moves to the nucleus. Once in the nucleus, the ICN interacts with members of the 
RBPJ or CSL (CBF1, Su(H) and LAG1) family of transcription factors and 
coactivators of the MAML (mastermind-like) family. ICN is unable to bind DNA 
on its own but needs CSL that directs it to specific targets. On the contrary, in 
absence of ICN CSL can form complexes with many co-repressor protein such as 
NcoR and SHARP. The nuclear complex composed by CSL/ICN/MAML recruits 
histone acetyltransferases, chromatin remodeling factors and mediator complex to 
assemble an active transcription complex on target gene promoters. (Fig. 3). 
 
 
Figure 3. Mechanism of Notch signaling. After the binding to a ligand, Notch receptor 
undergoes two proteolytic cleavages resulting in the release of the Notch intracellular domain 
(ICN) which transfers to the nucleus. Here ICN interacts with the CSL family of transcription 
factors, leading to conversion of the transcriptional co-repressor complex into an activator 
complex, and thus induce the expression of target genes. [CSL family: CBF1 for humans, 
Suppressors of hairless for drosophila, LAG for Caenorhabditis elegans, RBPJ in the mouse; Co-
R: co-repressor; TACE: TNF-α converting enzyme, also known as ADAM17; NICD: Notch 
intracellular domain] (Thurston et al., 2007). 
Regulation of either ligand or receptor availability at cell surface is very important 
to control Notch activation because each Notch molecule that undergoes 
proteolysis generates a signal and thus can only signal once. For this reason, 
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frequently ligand and/or receptor expression is spatially and temporally restricted. 
Moreover, ligands and receptors can be subjected to regulation by other signaling 
pathway and can have overlapping as well as distinct expression patterns during 
development. The outcome of Notch activation depends on cellular context and 
dose, it varies from differentiation to maintenance of stemness, apoptosis to cell 
survival, uncontrolled growth to growth arrest. (Aster and Blacklow, 2012; Kopan 
and Ilagan, 2009; Sanchez-Irizarry et al., 2004) . 
Among Notch target genes, very important are the helix-loop-helix transcription 
factor of the HES (Hairy Enhancer of Split) family such as HES1 and the HERP 
(Hes-Related repressor protein) transcription factor family. Also NRARP (notch-
regulated ankyrin repeat-containing protein), NFκB, DELTEX-1, NOTCH3, 
PTCRA (pre-TCRα or pTα) are Notch target genes (Radtke et al., 2004). 
Furthermore, Notch pathway directly controls key regulators of cell proliferation 
and metabolism such as p27Kip1, mTOR and c-MYC (Chan et al., 2007; Dohda et 
al., 2007; Palomero et al., 2006; Sharma et al., 2006; Weng et al., 2006).  
Sustained Notch activation can be deleterious, so cells must regulate ICN 
production and the duration of signaling. In most cells signal strength is regulated 
by ensuring that ICN half-life is short, indeed during the transcriptional activation 
process ICN is phosphorylated on its PEST domain and targeted for proteasomal 
degradation by the E3 ubiquitin ligase FBW7. This process eliminates ICN, 
disassembles the ternary complex and resets the cell for the next round of 
signaling.  
There are different modulators that regulate Notch signaling both at extracellular, 
cytoplasmic and nuclear levels. One possible modulation is fucose addition to 
specific residues within the EGF-like domain of Notch receptors, this can be 
further modified by the addition of N-acetylglucosamine mediated by Fringe 
proteins, a family of glycosyltransferase. This modification inhibits Jagged1-
mediated Notch1 signaling and potentiates Delta-mediated signaling. It remains to 
be determined whether glycosylation regulates the adhesion strength between 
Notch and its ligands. Among cytoplasmic modulators, there are Deltex1 and the 
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negative regulator Numb, which prevents nuclear translocation of ICN and so 
suppresses Notch signaling. Nrarp and Mint (Msx2-interacting nuclear target 
protein in mouse, SHARP in humans) are nuclear regulators of Notch activity: 
Nrarp interacts with ICN and CSL inhibiting Notch1 signaling and moreover is a 
Notch target gene, Mint is also a negative regulator because competes with ICN 
for binding to CSL (Radtke et al., 2004).  
 
1.2.2 Notch signaling and pathogenesis of T-ALL 
The first hint that Notch signaling could be important for T cell development was 
in 1991, when a chromosome translocation (7;9)(q34;q34.3) involving Notch1 
gene was discovered in patients with T-ALL (Ellisen et al., 1991). Several 
experiments and gain-of-function or loss-of-function genetic models have later 
confirmed the key role of Notch for T cell differentiation. The Notch-related 
oncogenic activity is almost exclusively restricted to T progenitors, suggesting a 
special developmental role for Notch in this lineage. Notch1 receptor, indeed, has 
a critical role in committing lymphoid precursors to the T versus B cell fate and 
Notch1-deficient mice lack T cell committed precursors in the thymus and contain 
increased numbers of early B cell precursors and mature B cells (Wilson et al., 
2001). Since Notch drives T cell development, in the bone marrow stem cell niche 
Notch signaling must be kept below a certain threshold, so prior to ETP stage 
Notch signaling level is very low. Notch signaling initiates in the early T cell 
precursors and increases as cells mature toward the DN3 stage of development. In 
the DN3 stage, T cell pass through a critical checkpoint - the β-selection - that 
requires both the signal generated by the pre-TCR and Notch1 signaling. DN3 
cells that receive both signals proliferate rapidly, on the contrary cells that don’t 
receive signals undergo apoptosis. Beyond β-selection, Notch signaling and 
NOTCH1 expression are down-regulated by mechanisms poorly understood and 
cell division finishes. NOTCH1 expression strongly correlate with the expression 
of c-MYC, which is a target of Notch required for the proliferative burst that 
accompanies β-selection. Down-regulation of NOTCH1 and c-MYC that takes 
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place after β-selection probably serves to limit the duration and extent of normal 
thymocyte proliferation. As a consequence, failure to down-regulate Notch1 
signaling may be an important feature of T-ALL pathogenesis because continued 
expression of NOTCH1 may block differentiation, allow the survival of cells that 
would normally be deleted and the expansion of cells. (Fig. 4) (Aster et al., 2008). 
 
 
Figure 4: Notch1 and T cell development. Different stages of T cell development, characterized 
by immunophenotypic features shown below each stage. Notch1 is required during maturation to 
the DN3a stage and its expression is down-regulated, together with c-MYC expression, after β 
selection [DN, CD4−/CD8− double negative; ISP, intermediate single positive; DP, CD4+/CD8+ 
double positive; TCR, T cell receptor] (Aster et al., 2008). 
 
 
In addition of these functions, Notch1 interacts with other genes implicated in the 
regulation of T cell development, such as IKAROS, E2A and NFκB. Ikaros is a 
transcriptional regulator critical for the development of all lymphoid-derived cells, 
which can be expressed in multiple isoforms with different DNA-binding 
activities. Beverly and Capobianco (Beverly and Capobianco, 2003) demonstrated 
that Notch and Ikaros cooperate in leukemogenesis. They found that Ikaros can 
bind the same regulatory elements as the Notch effector CSL, thus blocking the 
ICN-mediated activation of the reporter, and that the dominant negative Ikaros 
isoform may enhance CSL binding to enhancer/promoter elements. Combinations 
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of mutations that lead to loss of Ikaros transcriptional repression and gain Notch 
activity have been found even in other models (Dumortier et al., 2006; Lopez-
Nieva et al., 2004). E2A is a basic helix-loop-helix transcription factor required 
for normal lymphoid development and acts together with Notch signaling to 
initiate T-lineage specification. They interact at different levels, since E2A 
induces the expression of genes involved in Notch signaling - including HES1, 
NOTCH3, NOTCH1- and moreover E2A acts in concert with Notch signaling to 
induce pTα expression (Ikawa et al., 2006).  
Finally, there is also evidence of a complex interplay between Notch and NFκB 
signaling in transformed T cell progenitors. It has been recently demonstrated by 
Espinosa and colleagues that the Notch target gene HES1 represses the 
deubiquitinase CYLD, a negative regulator of IKK complex, thus sustaining 
NFκB activation. Moreover, they showed that the Notch-HES1-CYLD-IKK axis 
plays a critical role in the maintenance of T-ALL (Espinosa et al., 2010). 
The key role of Notch pathway in T cell development and in leukemia 
pathogenesis was discovered thanks to the identification of (7;9) translocation in 
patients with T-ALL. However this translocation is rare therefore it cannot 
account for pathogenesis of most T-ALL cases. In 2004 the scenario became 
clearer with the discovery that more than 50% of T-ALL cases present gain-of-
function mutations in NOTCH1 gene (Weng et al., 2004). Weng and colleagues 
identify mutations in the heterodimerization (HD) and PEST domain of Notch1 in 
most Notch-dependent T-ALL cell lines and in about 55% of primary T-ALLs. 
The most frequent NOTCH1 mutations (40-45% of tumors) are reported in the HD 
domain and they are generally single amino acid substitutions, short insertions or 
deletions that maintain the reading frame. As explained in the previous section, 
HD is the region designate to prevent inappropriate or premature activation of 
Notch receptors because in the off state the LNRs prevent access of 
metalloproteases to the S2 site by wrapping around the HD and occluding the S2 
cleavage site. In the heterodimerization domain two types of mutation can be 
found. The most common type I consists of substitutions at conserved residues or 
short in-frame insertions or deletions that destabilize the heterodimer stability. 
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Mutations of type II, relatively rare, are tandem insertions that result in the 
duplication of the S2 cleavage site. Both types of mutations render Notch1 
susceptible to ligand-independent cleavage at S2 site. PEST mutations are 
detected in 20-30% of tumors and consist of point mutations that introduce stop 
codons, insertions or deletions that cause a shift in the reading frame. PEST 
domain has an important role in regulating ICN1 turnover so mutations in this 
region may stabilize the intracellular Notch1 protein, owing to inhibition of 
FBW7-mediated degradation. FBW7 is an E3 ubiquitin ligase that forms part of 
the SCF complex that target ICN and other important cell cycle regulators 
including cyclin E and c-MYC. Interestingly, FBW7 inactivating mutations are 
reported in about 8-16% of T-ALL patients and frequently they are associated to 
NOTCH1 mutations, suggesting a synergistic pathogenetic effect. When mutated, 
FBW7 fails to bind target proteins or to tag them for degradation, in both cases 
prolonging their half-life (Kraszewska et al., 2012b; O'Neil et al., 2007). Different 
data suggest that there is a selective pressure for ever-increasing levels of Notch1 
activation during progression of human T-ALL so mutations in different domains 
are common. Mutations in both HD and PEST domains are indeed found in 10-
20% of primary T-ALLs and in most Notch-dependent cell lines (Fig. 5). 
NOTCH1 mutations in T-ALL are generally heterozygous and cells continue to 
co-express the other wild-type NOTCH1 allele.  
 
Figure 5: Distribution of Notch1 mutations in T-ALL. Each triangle stands for a mutation 
found in cell lines (black triangle) or primary T-ALL samples (white triangle).[ HDN and HDC, N- 
and C-terminal portions of the heterodimerization] (Aster et al., 2008). 
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After discovery of Notch1 as a key T-ALL oncogene, one of the first issues was 
identification of signaling pathways and target genes regulated by Notch1. As 
seen before, one direct transcriptional target of ICN1 is the transcription factor c-
MYC. c-MYC has a central role in regulating many aspects of cellular metabolism 
integral to the growth of cells so it is not surprising that Notch withdrawal causes 
downregulation of genes involved in protein synthesis, ribosome biogenesis and 
anabolic metabolism. Different recent papers highlight the existence of an 
important Notch1/c-MYC signaling axis in T-ALL cells, a feed-forward loop 
through which Notch1 and c-MYC reinforce the expression of genes required for 
the growth of T-ALL cells (Palomero et al., 2006; Sharma et al., 2006; Weng et 
al., 2006). Another link between Notch1 and growth pathways is represented by 
mTOR (mammalian target of rapamycin), key regulator of cell size and target of 
Notch (Chan et al., 2007). 
 
1.2.3 Notch signaling and other malignancies  
Since Notch pathway regulates many aspect of metazoan development and tissue 
renewal, misregulation or loss of Notch signaling are associated to multiple 
human disorders from developmental syndromes to adult onset diseases and 
cancer (Kopan and Ilagan, 2009). Regarding cancer, Notch signaling can be either 
oncogenic or tumor suppressive depending on the cellular context. Therefore it is 
not surprising that divergent context-dependent roles for Notch have emerged in 
cancer.  
In addition to the well-known role of Notch1 in T-ALL, recent studies uncovered 
an oncogenic function of Notch in other hematological malignancies. Several 
reports suggested a role for Notch signaling in chronic lymphocytic leukemia 
(CLL) but the genetic evidence arrived only in 2009, when the first NOTCH1 
mutations in CLL cells were reported, and was confirmed later by different 
studies. A mutation in exon 34 leading to PEST degron deletion was recovered in 
about 5-12% of CLL cases analyzed (Di Ianni et al., 2009; Fabbri et al., 2011; 
Puente et al., 2011). Moreover, gain-of-function mutations were detected in 
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approximately 12% of mantle cell lymphoma (MCL), an aggressive neoplasm 
derived from naїve mature B cells (Kridel et al., 2012). Most of the reported 
mutations lead to PEST degron deletions as observed in CLL. Interestingly, 
NOTCH1 mutations in CLL and MCL differ from those in T-ALL. Almost all of 
the mutations are PEST deletions and the majority (90% in CLL and >50% in 
MCL) consist of a deletion of the same 2 nucleotides in a codon. On the contrary, 
in T-ALL most frequent mutations are in the HD region and PEST mutations 
occur across a wide region, although the most common NOTCH1 mutation in 
PEST domain is the same deletion of two nucleotides as CLL and MCL. Beyond 
MCL, two groups identified mutations in NOTCH1 (Fabbri et al., 2011) or 
NOTCH2 (Lee et al., 2009) PEST domains in diffuse large B cell lymphoma. 
These findings suggest that Notch may have additional uncharacterized roles in 
the development or function of B cells (South et al., 2012). 
With regard to solid tumors, in the last years many studies showed a role of Notch 
pathway in the colorectal cancer (CRC) tumorigenesis. Notch1 activity is 
increased in CRC as a result of β-catenin-mediated upregulation of the ligand 
Jagged-1 (Rodilla et al., 2009), suggesting a cooperation between WNT and 
Notch pathways. Furthermore NOTCH1 is overexpressed in CRC and its 
expression correlates with the pathologic grade, progression and metastasis 
(Zhang et al., 2010). Beyond Notch1, also Notch3 has an oncogenic role in CRC 
since it is upregulated in metastatic samples and modulates the tumorigenic 
properties of CRC cells (Serafin et al., 2011). In invasive breast carcinoma 
overexpression of Notch1 and Jagged1 are associated to high grade tumors and 
poor prognosis (Reedijk et al., 2005) and aberrant Notch transcripts have been 
identified in breast carcinoma cell lines and primary tumors due to rearrangements 
of NOTCH1 or NOTCH2 genes (Robinson et al., 2011). Finally, enhanced 
expression and/or activity of Notch1 has been reported in tumor samples of 
patients with renal cancer (Bin Hafeez et al., 2009; Sjolund et al., 2008), prostate 
cancer (Bin Hafeez et al., 2009) and melanoma (Balint et al., 2005).  
Many genetic evidences emerging in the past years indicate a tumor suppressor 
role of Notch pathway in multiple types of human squamous cell carcinoma 
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(SCC), although the mechanisms remain to be defined. Different loss-of-function 
mutations in Notch1 indeed have been reported in cutaneous, head-neck and lung 
SCC (South et al., 2012).  
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1.3 THERAPIES IN T-ALL 
 
For many years, T-ALL has been considered and treated as a single entity but now 
is clear that it is a very heterogeneous malignancy, with extremely different 
biological features that contribute to disease development and patient outcome. 
Among T-ALL patients, only 70-80% of children and 40% of adults reach long-
term remission and the failure rate is likely due to insufficient understanding of T-
ALL biology (Kraszewska et al., 2012b). Further improvements in survival will 
demand a better understanding of T-ALL pathogenesis, decoding mechanisms of 
drug resistance and development of new therapeutic strategies. Identification of 
molecular pathways involved in T-ALL pathogenesis will uncover new genes 
whose protein products are suitable candidates for targeted therapy. For example, 
T-ALL patients that present the NUP214-ABL1 fusion or amplification of ABL1 
gene may take advantage of the use of imatinib or second-generation ABL kinase 
inhibitors (Pui and Evans, 2006). Recent studies have identified that the novel 
leukemia subtype “early T-cell precursors ALL” (ETP-ALL) displays a global 
transcriptional profile very similar to that of normal and myeloid leukemia 
hematopoietic stem cells. These findings suggest that patients with ETP-ALL may 
benefit from new therapies directed against the myeloid or stem cell features of 
this leukemia, such as high dose cytarabine or targeted therapies that inhibit 
cytokine receptor (Pui et al., 2012; Zhang et al., 2012).  
 
1.3.1 Risk-based treatment assignment 
Among each genetic subtype of ALL, there is quite a lot of heterogeneity due to 
differences in cooperating mutations in cells that undergo malignant 
transformation and because of variable host factors that influence drug 
metabolism and pharmacologic effects, such as genetic polymorphisms in genes 
that encodes drug-metabolizing enzyme, transporters, receptors and drug targets. 
Due to the disease heterogeneity, treatment must be directed according to risk 
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groups defined by both clinical and laboratory features in order to adapt the 
intensity of treatment among subsets of children with T-ALL.  
The risk-based treatment assignment mainly depends on factors that can be 
grouped in three categories:  
1. Patient characteristics. Among the most important patient features that 
affect prognosis there are the age at diagnosis (better prognosis for 
children aged 1 to 10 years compared to infants, older children and 
adolescent), the white blood cell count at diagnosis (WBC 5x104/µl is the 
cut-off between good and poor prognosis), central nervous system 
involvement at diagnosis (about 3% of patients have detectable CNS 
involvement with > 5 WBC/µ l in the cerebrospinal fluid, it is associated to 
a higher risk of failure) and testicular involvement at diagnosis (it occurs 
in approximately 2% of male, according to some protocols it is an adverse 
prognostic factor). 
2. Leukemic cell characteristics. Leukemic features that affect prognosis 
include the immunophenotype (for example ETP-ALL, subset with the 
poorer prognosis, is characterized by the distinctive immunophenotype 
CD1a- CD8- CD5weak with co-expression of stem cell or myeloid markers) 
and cytogenetics (high hyperdiploidy and hypodiploidy are positive and 
negative prognostic factors, respectively; MLL gene rearrangements are a 
negative prognostic factor; ETV6-RUNX1 rearrangement is a positive 
prognostic marker) 
3. Response to initial treatment. Since treatment response is influenced by the 
drug sensitivity of leukemic cells and host pharmacogenomics and 
pharmacodynamics, the rapidity of leukemic cells clearance following 
onset of treatment and the levels of residual disease at the end of the 
induction have a strong prognostic significance. The response to initial 
treatment can be evaluated in different ways. The first is the MRD 
(minimal residual disease) determination that can be obtained by PCR of 
patient specific Ig/TCR rearrangement or by flow cytometry, if a 
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leukemia-specific immunophenotype can be identified. Both techniques 
are specific and sensitive (detection of 1 leukemic cell in 1x105 normal 
cells), afford levels that cannot be attained through traditional morphologic 
assessments (detection of 1 leukemic in 20 normal cells). In the AIEOP-
BFM (Associazione Italiana Ematologia Oncologia Pediatrica- Berlin 
Frankfurt Münster) ALL 2000 trial the MRD status at day 78 has been 
proposed as the most important predictor for relapse in patients with T-
ALL because MRD accounts for all the leukemic-cell biological features 
(including drug sensitivity), host pharmacodynamics and 
pharmacogenomics, and efficacy of the treatment regimen. Besides MRD 
determination, a good response to initial treatment can be established by 
reduction of leukemic cells to less than 5% in the BM within 7 or 14 days 
following initiation of therapy or by reduction in peripheral blast count to 
less than 1000/µl after steroid induction prophase. Finally leukemia cell 
response to treatment can be evaluated in the peripheral blood 7-10 days 
after the beginning of multiagent chemotherapy, patients with persistent 
circulating leukemic cells are at increased risk of relapse. 
Different study groups stratified patients into prognostic risk groups by 
considering various factors among those mentioned above. The BFM (Berlin-
Frankfurt-Münster) protocols base the risk stratification of pediatric patients only 
on treatment response criteria. In addition to prednisone response, treatment 
response is evaluated by MRD determination at two time points, precisely at the 
end of induction (week 5) and at the end of consolidation phase (week 12). 
According to this classification patients are divided in: Standard Risk if they are 
MRD-negative at both time points analyzed, Intermediate Risk if they have 
positive MRD at week 5 and low MRD (<10-3) at week 12 and High Risk if they 
have high MRD (≥10-3) at week 12 or if they are poor responder to prednisone 
prophase, regardless of subsequent MRD (NCI web site, see reference). 
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1.3.2 Treatment of childhood T-ALL 
Treatment of childhood T-ALL is based on specific protocols designed according 
to risk group stratification. This approach allows patients with favorable clinical 
and biological features, who are likely to have a very good outcome, to receive a 
relatively mild treatment, whereas patients with poor prognosis receive a more 
aggressive therapy that - albeit potentially more toxic - may eventually increase 
survival. Therapy of T-ALL is generally divided into three phases: remission 
induction therapy followed by consolidation/intensification therapy and then 
maintenance/continuation treatment. 
The primary goal of remission induction is the eradication of more than 99% of T-
ALL cells from blood and bone marrow and to restore normal hematopoiesis and 
a normal performance status. It is very important to completely eradicate leukemic 
cells also from extramedullary sites, since T-ALL often involves these sites. 
Although protocols for pediatric ALL consider the same classes of drugs for 
remission induction, there is no consensus on what constitutes an optimal 
regimen. Remission induction therapy usually includes a glucocorticoid, 
vincristine and asparaginase because they have distinct mechanisms for their 
antileukemic effects and may act synergistically. Prednisone has been the 
glucocorticoid most used but recently dexamethasone replaced it in different 
clinical trials because of its long half-life and excellent CNS penetration. 
Cytotoxic effects of these class of drugs are due to the glucocorticoid-mediated 
inhibition of cytokine production, alteration of oncogenes expression and 
induction of cell cycle arrest and apoptosis (Inaba and Pui, 2010). In some 
protocols, patients are treated also with an anthracycline such as doxorubicin or 
daunorubicin. It has been tried to intensify induction therapy in order to reduce 
leukemia burden and prevent drug resistance, but intensive induction therapy led 
to increased morbidity and mortality.  
Once remission has been achieved and normal hematopoiesis is restored, patients 
undergo consolidation/intensification therapy. The intensity of chemotherapy 
varies considerably depending on risk group assignment and, such as remission 
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induction, also for the consolidation/intensification therapy there is no consensus 
on the best regimens and their duration. This phase of treatment can be based on 
intermediate-dose or high-dose methotrexate, drugs similar to those used in the 
first phase (asparaginase, vincristine, dexamethasone, with or without 
anthracycline), different drug combinations with little known cross-resistance to 
the induction therapy drugs, including cyclophosphamide, cytarabine and 
thiopurine or combinations of the above.  
Finally, patients are subjected to maintenance/continuation treatment in order to 
eliminate residual leukemia cells. Patients with ALL require prolonged 
continuation therapy, at least two years, and attempts to shorten this phase have 
entailed poor results both in children and adults. The maintenance/continuation 
therapy is based on the combination of methotrexate and mercaptopurine 
administrated weekly and daily respectively, with or without pulses of 
dexamethasone and vincristine (Pui and Evans, 2006; Pui et al., 2012). In some 
protocols boys are treated longer than girls because prognosis for girls is slightly 
better for reasons that are not well understood (NCI web site). 
As mentioned before, in approximately 3% of T-ALL patients there is a detectable 
CNS involvement at diagnosis, with ≥5 WBC/µl recovered in the cerebrospinal 
fluid. Potentially the majority of children will develop overt CNS leukemia 
therefore all pediatric patients should receive systemic combination chemotherapy 
together with CNS prophylaxis. Standard treatment options include intrathecal 
chemotherapy with methotrexate alone or in combination with cytarabine and 
hydrocortisone, CNS-penetrant systemic chemotherapy based on dexamethasone, 
L-asparaginase and high-dose methotrexate with leucovorin rescue and cranial 
radiation. Once more, the type of CNS-therapy used is based on the patient’s risk 
group and the risk of CNS-relapse. Cranial radiation is usually directed only to the 
highest risk for subsequent CNS relapse, the use of cranial radiation indeed has 
decreased significantly in the past years especially for pediatric patients due to 
many late-occurring injuries such as second cancer, neurocognitive impairment 
and multiple endocrinopathy. In very high risk patients that still receive cranial 
radiation, the dose has been significantly reduced. (Pui and Evans, 2006; Pui et 
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al., 2012). Intrathecal chemotherapy is usually started at the beginning of 
induction, intensified throughout consolidation and in some protocols continued 
during the maintenance phase (NCI web site).  
In the event of relapse, initial treatment consists in a four-drug reinduction 
regimen similar to that administrated to newly-diagnosed high risk patients or a 
therapy with high-dose methotrexate and high-dose cytarabine. Patients with 
refractory or multiple-relapsed leukemia are commonly treated with a 
combination of clofarabine, cyclophosphamide and etoposide (NCI web site).  
Leukemia patients have a limited bone marrow reserve of normal hematopoietic 
cells therefore it can be necessary to opt for prophylactic antibiotics and 
antifungal agents to prevent serious infections, particularly if high-dose 
dexamethasone therapy is prolonged or combined with other cytotoxic 
chemotherapies (Inaba and Pui, 2010).  
Finally several novel nucleoside analogues have revealed promising results in the 
treatment of T-ALL, such as clofarabine, forodesine and nelarabine. The last is the 
most studied, it is a soluble nucleoside analogue that is converted in the active 
nucleotide and then is incorporated into DNA, resulting in chain termination and 
cell death. The nucleotide preferentially accumulates in leukemic cells compared 
to normal cells. Other novel agents in the early phase of clinical testing include 
FLT3 inhibitors and γ-secretase inhibitors (GSI). As described before, γ-secretase 
is the enzyme that catalyzes the release of the ICN, the active form of Notch 
receptor. GSI were originally created for Alzheimer’s disease, since γ-secretase is 
involved in its pathogenesis, and have subsequently been studied also in T-ALL. 
Unfortunately, first generation GSI cause severe gastrointestinal toxicity due to 
simultaneous blockade of all Notch receptors, which prevented their clinical 
application (Fielding et al., 2012; Pui and Evans, 2006). 
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2. AIM OF THE STUDY 
 
T-cell acute lymphoblastic leukemia is an hematologic disease representing 
approximately 15% of the newly diagnosed cases of ALL in children and 25% in 
adults. Although therapeutic strategies have considerably improved in the last 
years, only 70-80% of pediatric and 40% of adult patients achieve long-term 
remission. Therefore it is necessary to develop and study new therapeutic 
approaches in order to convert these patients in curable.  
Many studies focus the Notch pathway, because its role during T cell 
development is well established and because mutations in NOTCH1 gene are 
found in about 50-55% of T-ALL cases. Previous attempts to target Notch 
signaling in T-ALL were mainly based on administration of GSI (gamma-
secretase inhibitors), which unfortunately disclosed poor efficacy and severe 
gastro-intestinal toxicity due to simultaneous inhibition of Notch1 and Notch2 
signaling in gut epithelial cells.  
Starting from these evidences, the main purpose of the study was to investigate 
therapeutic efficacy of selective targeting of Notch1, which may overcome some 
limits of broad-spectrum therapies. To these end, we generated a clinically 
relevant model of T-ALL and used it to test the therapeutic and biological effects 
of a novel neutralizing monoclonal antibody directed against human Notch1. To 
investigate mechanisms involved, we analyzed effects of the therapy on cell death, 
proliferation and gene expression. Moreover, we identified new predictive 
biomarkers of response which could be helpful for clinical development of this 
drug and investigated possible synergistic effects of Notch1 blockade with 
consolidated drugs used for T-ALL patients. 
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3. MATERIALS AND METHODS 
 
3.1 T-ALL xenografts establishment and tumorigenicity assay  
Primary T-ALL cells (PDTALL) were obtained from bone marrow (BM) of 
newly diagnosed pediatric patients, according to the guidelines of the local ethics 
committees. For xenografts establishment, 6- to 9-weeks-old mice were injected 
intravenously (i.v.) with 10 x 106 T-ALL cells in 300 µl of Dulbecco's Phosphate 
Buffer Saline (PBS). NOD/SCID mice were purchased from Charles River 
(Wilmington, MA). Procedures involving animals and their care conformed with 
institutional guidelines that comply with national and international laws and 
policies (EEC Council Directive 86/609, OJ L 358, 12 December, 1987). T-ALL 
engraftment was monitored by periodic blood drawings and flow cytometric 
analysis of CD5 and CD7 markers over a 5-month period. To test the effect of 
Notch1 blockade on leukemia engraftment, NOD/SCID mice were treated with 
anti-human Notch1 mAb OMP-52M51 (Oncomed Pharmaceuticals Inc., 
Redwood, CA) or control antibody (Rituximab, Roche, Basel, Switzerland) 
administrated intraperitoneally (i.p, both used at 20 mg/Kg) two days after i.v. 
injection of T-ALL cells (5x106 cells/mouse). Anti-Notch1 or control antibody 
were subsequently administrated weekly for an average of 3 doses (6 mice/group). 
In the late intervention trial, administration of OMP-52M51 started 11 days after 
leukemia cell injection, followed by a second dose one week later. In the 
experiment with combination of dexamethasone and anti-Notch1, the first was 
administrated i.p everyday (used at 10 mg/Kg) while anti-Notch1 was 
administrated weekly as starting 11 days after cells injection. In all experiments, 
mice were inspected twice weekly to detect early signs and symptoms of leukemia 
and blood was drawn to measure T-ALL cell engraftment. 
3.2 Cytofluorimetric analysis and cell sorting  
Anti-human FITC-conjugated CD5 and PE-Cy5-conjugated CD7 antibodies 
(Coulter, Fullerton, CA) were used for the detection of T-ALL cells in blood, 
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spleen and bone marrow samples. Apoptosis and proliferation were evaluated by 
the Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Penzberg, Germany) 
and the AlexaFluor 488-labeled Ki67 staining (BD Biosciences, San Jose, CA) 
respectively. In order to exclude murine cells from the analysis, only human CD5+ 
cells were considered for both apoptosis and proliferation assays. Samples were 
analyzed on Beckman Coulter EPICS-XL Flow Cytometer (Coulter) or BD LSRII 
Flow Cytometer (BD Biosciences). Dot plots images were processed by Flow Jo 
software (TreeStar, Ashland, OR). For fluorescence glucose analysis, cells were 
incubated with 2-N-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-
glucose (2-NBDG) for 1 minute and analyzed at FACS without washing, 
considering only human CD5+ cells.  
T-ALL cells from bone marrow and spleen were incubated with PE-Cy5-
conjugated antibody against human CD5 and sorted on a BD FACS Aria III cell 
sorter (BD Biosciences). Relative percentages of the CD5+ subpopulation were 
calculated based on viable gated cells (as indicated by physical parameters, side 
scatter and forward scatter). After sorting, an aliquot of the sorted cells was used 
to check the purity of the population.  
3.3 Optical imaging of tumors  
To perform in vivo imaging, leukemia cells were transduced by a lentiviral vector 
encoding the luciferase gene. In vivo bioluminescence images were acquired at 
several time points after cells injection on IVIS Imaging System (Xenogen 
Corporation, Alameda, CA). Eight minutes before imaging, animals were 
anesthetized and injected i.p. with 150 mg/kg of D-luciferin (Biosynth AG, Staad, 
Switzerland) in Dulbecco's Phosphate Buffer Saline (PBS). During acquisitions 
animals were maintained under slight gas anesthesia (isoflurane 2%). Signal 
intensity was quantified as average radiance within a region of interest prescribed 
around the tumor sites (photons/s/cm2) using the LivingImage® software 
(Xenogen).  
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3.4 Reverse Transcription-PCR and quantitative PCR (qPCR)  
Total RNA was isolated using TRIzol Reagent according to manufacturer's 
instructions. cDNA was synthesized from 1-1.5 µg of total RNA using High 
Capacity RNA-to-cDNA kit. For qPCR analysis, the SYBR Green dye and ABI 
Prism 7900 Sequence Detection System were used. Relative quantification was 
done using the ∆∆Ct method, normalizing to β2-microglobulin mRNA. Primers 
used for qPCR analysis are: CR2-for: 5'-CTGCGGTTCAGTGTCCACAT-3'; 
CR2-rev: 5'-GGTGAAGCCAAACATGCAAGC-3' ; DTX-1-for: 5'-
GTGGGCTGATGCCTGTGAAT-3'; DTX-1-rev: 5'-
CGAGCGTCCTCCTTCAGCAC-3'; HES1-for: 5'-
GGCGGCTAAGGTGTTTGGAG-3'; HES-1 rev: 5'-
GGAAGGTGACACTGCGTTGG-3'; NOTCH3-for: 5’-
CAAGGGTGAGAGCCTGATGG-3’; NOTCH3-rev: 5’- 
GAGTCCACTGACGGCAATCC-3’; pTa-for: 5’- 
ATGGTGGTGGTCTGCCTGGT-3’; pTa-rev: 5’-
AGTTGGTCCAGGTGCCATCC-3’; β2-microglobulin-for 5'-
TGCTGTCTCCATGTTTGATGTATCT-3'; β2-microglobulin-rev: 5'-
TCTCTGCTCCCCACCTCTAAGT-3'.  
For analysis of the Notch pathway activation, 21 Notch target genes (see list 
below in Table I) were evaluated in duplicates by Custom TaqManArray Cards 
using TaqMan Universal PCR Master Mix and ABI Prism 7900 Sequence 
Detection System. Relative quantification was done using the ∆∆Ct method, 
normalizing to β2-microglobulin mRNA. All reagents were obtained from Life 
Technologies, Paisley, UK. 
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Gene  Assay ID Description 
B2M B2M-Hs99999907_m1 beta-2-microglobulin 
p27 CDKN1B-Hs00153277_m1 cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
p18 CDKN2C-Hs00176227_m1 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 
CR2 CR2-Hs00153398_m1 complement component (3d/Epstein Barr virus) receptor 2 
DTX1 DTX1-Hs00269995_m1 deltex homolog 1 (Drosophila) 
GAPDH GAPDH-Hs99999905_m1 glyceraldehyde-3-phosphate dehydrogenase 
GIMAP5 GIMAP5-Hs00218095_m1 GTPase, IMAP family member 5 
HES1 HES1-Hs00172878_m1 hairy and enhancer of split 1, (Drosophila) 
HES4 HES4-Hs00368353_g1 hairy and enhancer of split 4 (Drosophila) 
HMBS HMBS-Hs00609293_g1 hydroxymethylbilane synthase 
LZTFL1 LZTFL1-Hs00220450_m1 leucine zipper transcription factor-like 1 
MYC MYC-Hs99999003_m1 v-myc myelocytomatosis viral oncogene homolog (avian) 
NOTCH3 NOTCH3-Hs00166432_m1 Notch homolog 3 (Drosophila) 
PCGF5 PCGF5-Hs00737074_m1 polycomb group ring finger 5 
PGK1 PGK1-Hs99999906_m1 phosphoglycerate kinase 1 
PRMT1 PRMT1-Hs00266002_m1 protein arginine methyltransferase 1 
pTa PTCRA-Hs00300125_m1 pre T-cell antigen receptor alpha 
PTPRC PTPRC-Hs00174541_m1 protein tyrosine phosphatase, receptor type, C 
RHOU RHOU-Hs00221873_m1 ras homolog gene family, member U 
RPL10A RPL10A-Hs01912344_uH ribosomal protein L10a 
SHQ1 SHQ1-Hs00250772_m1 SHQ1 homolog (S. cerevisiae) 
SKP2 SKP2-Hs00180634_m1 S-phase kinase-associated protein 2 (p45) 
TASP1 TASP1-Hs00214554_m1 taspase, threonine aspartase, 1 
ZAP70 ZAP70-Hs00277148_m1 zeta-chain (TCR) associated protein kinase 70kDa 
 
Table I: List of the 21 Notch target genes analyzed in Custom TaqManArray Cards. 
 
3.5 NOTCH1 and FBW7 mutational analysis 
Genomic DNA was extracted from T-ALL cells derived from xenografts with 
Easy DNA kit (Life Technologies). NOTCH1 and FBW7 mutation analysis was 
performed as describe in (Sulis et al., 2008; Thompson et al., 2007) in 
collaboration with Prof. Adolfo Ferrando (Dept. of Pediatrics, Columbia 
University Medical Center, New York, USA). 
3.6 Clonality analysis of TCR genes in T-ALL cells 
PCR analysis to detect TCRD, TCRG and TCRB rearrangements was performed 
using methods published elsewhere (van Dongen et al., 2003; van Dongen et al., 
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1999). TCR gene rearrangements were analyzed in the primary leukemia cells at 
diagnosis and in the cells obtained from xenografts, in order to check if clonality 
was maintained after passage into NOD/SCID mice. Clonal gene rearrangements, 
identified by homo/heteroduplex analysis, were sequenced by dye-terminator 
cycle sequencing kit on ABI Prism 310 (Life Technologies) (Germano et al., 
2001) in collaboration with Prof. Giuseppe Basso’s lab (Lab. Oncoematologia, 
Dip. di Salute della Donna e del Bambino, Università di Padova). 
 
3.7 Preparation of cRNA, GeneChip microarray analysis and data 
normalization  
Total RNA was isolated using TRIzol Reagent (Life Technologies) according to 
manufacturer's instructions. Sense-strand cDNA from total RNA was prepared 
using the Ambion WT Expression Kit (Life Technologies, Paisley, UK). The 
cDNA was then fragmented and labeled using the Affymetrix GeneChip  WT 
Terminal Labeling kit (Affymetrix, Santa Clara, CA) .Total RNA and cRNA 
quality was controlled by Agilent RNA 6000 Nano Kit and Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). cDNA was quantified by 
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
Labeled sense-strand cDNA was used for screening of GeneChip Human Exon 
1.0 ST Array (Affymetrix). Three independent experiments were performed. Each 
biological replicate consisted of T-ALL cells from the bone marrow of different 
mice that were pooled before sorting and RNA extraction (n=3-6 samples per 
pool). Hybridization and scanning was conducted on the Affymetrix platform. 
Based on assessment of RNA quality and on quality control analyses (including 
MAplots, boxplots and post-normalization hierarchical clustering), two anti-Notch 
1 (aN1) and three control Ab (ctrl-Ab) treated samples were deemed suitable for 
data analysis. Bioinformatics and statistical analyses were performed in R 
(http://www.r-project.org) and Bioconductor version 2.10 (Gentleman et al., 
2004). We processed core-probe-level signal using robust multi average (RMA) to 
generate quantile-normalized gene-level signal estimates. Affymetrix controls and 
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probesets that were not mapping known genes were excluded from further 
analysis. Two independent filters, based on overall variance and overall mean 
criteria, were applied to remove the probesets falling in the lowest quartile of 
mean expression and variance, respectively. Differential expression analysis was 
performed by linear model, moderating the t-statistics by empirical Bayes 
shrinkage, using the limma package (Smyth, 2004). The Benjamini-Hochberg 
false discovery rate (BH FDR) procedure was applied to correct for multiple 
testing and differentially expressed genes between aN1 and ctrl Ab were selected 
using a BH-adjusted p< 0.05 and absolute fold-change>1.5 as cutoff. 
3.8 Gene Set Enrichment Analysis (GSEA)  
We performed GSEA (Subramanian et al., 2005) to evaluate functional 
significance of curated sets of genes. Genes were ranked by decreasing moderated 
t-statistics and GSEA pre-ranked was run with default parameters. We tested the 
significance of gene sets in the "c2.all" collection from the Molecular Signatures 
Database v3.0 (http://www.broadinstitute.org/gsea/msigdb/index.jsp), consisting 
of 3272 gene sets corresponding to biological pathways, gene signatures 
published in PubMed, and genes sets curated by domain experts, including the 
MYC Target Gene Database. 
3.9 Animal PET studies  
Tumor bearing mice were investigated using a YAP-(S)-PET II (ISE srl, Pisa, 
Italy) small animal scanner. [18F]FDG was injected with a radiochemical purity 
greater than 99%. and animals (n=5 per group) were evaluated when control mice 
developed signs of illness (15 days after T-ALL cell injection). [18F]FDG PET 
studies were performed as follows: animals were injected in a tail vein with 4.28 ± 
0.24 MBq of the tracer and images were acquired 60 minutes after tracer injection 
for 30 minutes. During acquisitions animals were maintained under slight gas 
anesthesia (isoflurane 2%). PET studies were acquired in three dimensional mode 
and all images were reconstructed by using the EM (Expectation Maximization) 
algorithm. Data were corrected for the physical decay of fluorine 18 (t1/2: 109.8) 
and transformed in absolute radioactivity concentration values (MBq/gr) after 
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calibration of the tomography using a standard phantom and considering tissue 
density equal to that of water. Quantification analysis were performed using 
PMOD 2.7 software. For each animal, maximal tumor to background ratios 
(Tmax/B) volume of radioactivity uptake (Volmetab) were measured. To this aim, 
PET images were thresholded as previously validated and described by Krak et al. 
to create masks for the automatic extraction of tracer distribution volume 
(Brepoels et al., 2007; Krak et al., 2005). We considered as upper threshold value 
the maximum value of radioactivity concentration in tumor, and as lower 
threshold a value calculated from the mean between the maximum uptake or and 
the radioactivity concentration present in surrounding region considered as 
background (torax muscle). This threshold method allowed to automatically 
extract the metabolic tumor volume (cm3), the maximum and the mean uptake of 
the tumor. Standardized Uptake Value (SUV) was calculated according to the 
formula: SUV = (tumor concentration activity / injected activity) / animal weight 
[g]). These experiments were done in collaboration with the Dr. Rosa Maria 
Moresco’s lab (Nuclear Medicine Department, San Raffaele Scientific Institute; 
Fondazione Tecnomed, University of Milan Bicocca; IBFM-CNR, Milan, Italy) 
3.10 Statistical analysis  
Results were expressed as mean value ± SD. Statistical analysis of data was 
performed using Student's t-test or Mann-Whitney test. Differences were 
considered statistically significant when P ≤ 0.05. 
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4. RESULTS 
 
4.1 Establishment of a clinically relevant model of T-ALL 
Xenografts were established by i.v. injection of primary T-ALL cells into 
NOD/SCID mice (1x107 cells/mouse). Leukemia engraftment was monitored by 
periodic blood drawings and flow cytometric analysis of the expression of human 
T cell-specific surface markers (CD5, CD7). Engraftment rate after a 5-month 
observation period was 52% and so far we obtained a collection of n=30 
xenografts. As reported in Table II, pediatric patients from which T-ALL cells 
were obtained were classified according to phenotype, MRD class risk and 
prednisone sensitivity. T-ALL cells obtained from xenografts were periodically 
analyzed by molecular analysis in order to confirm that the same TCR 
rearrangement was found in the primary leukemia cells from patients and in the 
matched xenograft.  
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Sample ID Age (years) Phenotype Risk PGR/PPR NOTCH1 status FBW7 status
PDTALL6 13 T int MR PGR wt wt
PDTALL9 9 Early T HR (deceased) wt wt
PDTALL13 5 T HR (deceased) wt wt
PDTALL14 8 Int/mat MR PPR wt wt
PDTALL15 7 T HR PPR wt wt
PDTALL16 5 T mat MR PPR wt wt
PDTALL18 6 T int MR PPR wt wt
PDTALL28 12 T int N/A PGR wt N/A
PDTALL1 12 T int SR PGR HD mut. Mut.
PDTALL4 N/A T MR PGR HD mut. Mut.
PDTALL7 5 T int MR PGR HD mut. wt
PDTALL10 10 Early T MR PGR HD mut. Mut.
PDTALL11 6 Thym MR PPR HD mut. wt
PDTALL20 11 T int HR PGR HD mut. wt
PDTALL21 9 T int MR PGR HD mut. wt
PDTALL5 2 T int MR PGR PEST mut. wt
PDTALL12 4 Early T MR PGR PEST mut. wt
PDTALL22 16 Early T MR PGR PEST mut. wt
PDTALL8 3 T int MR PPR HD+PEST mut. wt
PDTALL26 9 T int N/A PGR HD+PEST mut. N/A
PDTALL19 16 Early T relapse relapse PPR HD+TAD mut. Mut.
PDTALL27 9 Early T N/A PGR HD+TAD mut. N/A
PDTALL23 8 T mat N/A (deceased) N/A N/A
PDTALL24 4 T int MR PGR N/A N/A
PDTALL25 8 T MR PPR N/A N/A
PDTALL29 16 T HR PPR N/A N/A
PDTALL30 8 Early T N/A N/A N/A N/A
PDTALL31 14 T N/A N/A N/A N/A
PDTALL32 17 Early T N/A N/A N/A N/A
PDTALL33 6 T int N/A N/A N/A N/A
 
Table II: Pediatric T-ALL patients were classified for phenotype, risk (according to the MRD 
classification) and response to therapy. Patients age was 2-17 years. Mutational status of NOTCH1 
and FBW7 are also reported. For PDTALL4, PDTALL6, PDTALL7 and PDTALL10 the genetic 
analysis was performed using DNA from patients at diagnosis, while for the others DNA from 
xenografts was utilized. [N/A= not available; SR= standard risk, MR= medium risk, HR= high 
risk; PGR= prednisone good responder, PPR= prednisone poor responder; HD= 
heterodimerization domain, PEST= proline-glutamic acid-serine-threonine-rich domain, TAD= C-
terminal transcription activation domain] 
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4.2 Analysis of NOTCH1/FBW7 mutations and Notch activity in 
T-ALL cells 
Genomic DNA obtained from both primary T-ALL samples and xenografts was 
analyzed in order to identify possible mutations in NOTCH1 or FBW7 genes. 
Genetic analysis disclosed an heterogeneous NOTCH1 and FBW7 genetic status. 
Approximately 63% of PDTALL samples present at least one mutation in 
NOTCH1 gene, including the hetero-dimerization domain HD (n=7), PEST 
domain (n=3), HD + PEST (n=2) or HD + TAD (n=2). Moreover, 21% (n=4) of 
the samples displayed also mutations in FBW7 gene. These percentages are 
consistent with those reported in literature. Specific mutations are reported in 
Table II. 
Expression levels of some Notch target genes including CR2, DTX-1, HES1, 
NOTCH3 and pTα were measured by qRT-PCR in order to correlate the 
mutational status to the levels of activity of the Notch pathway. In general there 
was a good correlation between the NOTCH1 and FBW7 genetic status and the 
expression levels of Notch-related transcripts since mutated xenografts disclosed a 
higher pathway activation compared to wild type samples. Exceptions were 
PDTALL6 and PDTALL18, two xenografts with relatively sustained Notch 
signaling in the absence of NOTCH1/FBW7 mutations, and PDTALL21, a 
xenograft with low Notch signaling notwithstanding an HD mutation (Fig. 6). 
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Figure 6:. Expression levels of Notch target genes in T-ALL xenografts and correlation with 
NOTCH1/FBW7 genetic status. Expression levels of CR2, DTX-1, HES1, NOTCH3 and pTα was 
determined by qRT-PCR and normalized to normal thymocytes (n=4 samples). The mutational 
status of NOTCH1 and FBW7 is reported below each xenograft. 
 
 
 
 
 
 
 
 
 
 
 43 
 
4.3 Notch-blockade by receptor-specific antibody as a novel 
therapeutic option for T-ALL 
The systemic T-ALL model thus generated was exploited to test the biological 
and therapeutic activity of a human Notch1-specific neutralizing antibody. OMP-
52M51 was generated by immunizing mice with a fragment of human Notch1 
protein consisting of the LNR plus HD domains and was selected by Oncomed 
Inc., among large panels of antibodies developed, due to its optimal antagonist 
function in ligand-dependent reporter gene assays and in vivo xenograft models. 
OMP-52M51 was indeed able to efficiently reduce Notch1 signaling driven in 
response to DLL4, Jag1 or Jag2 ligands in a dose-dependent way (Fig. 7, top 
panel) and to significantly block subcutaneous growth of HPB-ALL cells in mice 
(Fig. 7, bottom panel). 
 
 
 
Figure 7: OMP-52M51 is an effective inhibitor of human Notch1 signaling in response to both the 
DLL family or the Jag family of Notch ligands. Top: A Notch dependent luciferase reporter gene 
regulated by CBF binding sites was transfected into PC-3 cells along with an expression vector 
encoding human Notch1. Cells were exposed to immobilized DLL4, Jag1 or Jag2 as indicated and 
to varying concentrations of anti-Notch1. Bottom: 5x106 HPB-ALL cells were injected 
subcutaneously in NOD/SCID mice. Treatment was initiated 13 days later when tumor volumes 
averaged approximately 110 mm3 and continued for the duration of the experiment. Mice received 
either 15 mg/kg of a control antibody or OMP-52M51 twice weekly, administered by IP injection 
[n=10 mice per group]. 
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In order to evaluate the efficacy of this mAb in a close-to-clinic model, we 
assessed its effects in n=4 xenografts bearing different NOTCH1/FBW7 mutations 
and in n=3 xenografts with wild-type NOTCH1 sequence. Initially, early 
intervention trials were carried out as represented in the following schematic 
model: 
 
In these experiments, administration of anti-Notch1 or control antibody started 2 
days after i.v. injection of T-ALL cells (6 mice/group) and tumor burden in 
treated compared to control mice was monitored by periodic flow cytometric 
analysis of blood samples for the expression of human CD5 and CD7. At the 
appearance of signs of illness in control mice, both groups were sacrificed and 
therapeutic response was evaluated by analysis of percentage of leukemic cells, 
levels of apoptosis and proliferation in BM and spleen.  
At sacrifice, we detected significant reductions in the percentage of blasts both in 
the blood, in the spleen and in the BM in treated compared to control mice in 
PDTALL11, PDTALL12, PDTALL8 and PDTALL19. In contrast, PDTALL13, 
PDTALL16 and PDTALL18 were substantially resistant to Notch1 blockade. 
Interestingly, the therapeutic response matched the NOTCH1/FBW7 genetic status 
of the T-ALL xenografts: the presence of mutations in NOTCH1 in PDTALL11, 
PDTALL12, PDTALL8 and PDTALL19 xenografts correlated with good 
response to anti-Notch1 therapy, whereas the three xenografts with parental 
NOTCH1/FBW7 sequences were poor responders.  
Evaluation of CD7+ cells in the three districts analyzed are reported in figure 8, 
furthermore these results were confirmed either by measurements of CD5+ cells as 
additional read-out of leukemia (data not shown). 
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Figure 8: Anti-Notch1 inhibits growth of Notch1-driven T-ALL xenografts. Top: Measurement of 
circulating blasts by flow cytometry in the blood. Middle: Percentage of leukemic cells in the 
spleen at sacrifice. Bottom: Levels of T-ALL cells in the bone marrow of treated or control mice 
evaluated at sacrifice. Statistically significant differences in ctrl Ab versus anti-Notch1 samples are 
indicated (* P<0.05; ** P<0.001). 
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Interestingly, a clear reduction in the surface CD7 expression was measured in 
samples of anti-Notch1 responder xenografts (Fig. 9) but not in those poor 
responders. In contrast, CD5 levels were not down-modulated by treatment. The 
marked reduction in CD7 expression was a consistent trait following anti-Notch1 
therapy and it was strictly correlated to the therapeutic response, suggesting that 
this parameter could be considered a candidate predictive marker.  
 
 
Figure 9: Representative flow cytometric analysis of CD5 and CD7 expression in spleen (top 
panel) and BM (bottom panel) of ctrl Ab and anti-Noch1 treated mice. This sample shows marked 
down-regulation of CD7 expression levels following anti-Notch1 therapy. 
 
Furthermore, anti-Notch1 therapy was associated to an increase in the levels of 
apoptosis and a significant decrease of T-ALL cell proliferation both in spleen and 
BM (Fig. 10). 
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Figure 10: Effects of anti-Notch1 treatment on apoptosis and proliferation. At sacrifice, levels of 
apoptotic leukemic cells in the spleen (Top panel) and in the bone marrow (Middle panel) of 
treated or control mice were measured by annexin V labeling and flow cytometric analysis (n=6 
mice/group). Bottom panel, evaluation of CD5+ cells proliferation by Ki67 staining and flow 
cytometric analysis in PDTALL19 is reported (one representative experiment). Statistically 
significant differences in the two groups of samples are indicated (*P<0.05, **P<0.001) 
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In one xenograft (PDTALL19) the effect of anti-Notch1 therapy was monitored 
by imaging following labeling of T-ALL cells with a luciferase-expressing 
lentiviral vector. Optical imaging confirmed the reduction in the tumor 
engraftment after anti-Notch1 administration at various time points of analysis 
(Fig. 11, top panel). It should be noted that at day 17 anti-Notch1-treated mice 
lacked detectable signals while leukemia was widespread in control mice, in 
particular involving the spleens and the femurs.  
In support of these findings, effects of anti-Notch1 treatment were detected also 
by [18F]FDG PET imaging. These studies disclosed that [18F]FDG uptake was 
very high in PDTALL19 xenografts receiving the control antibody, particularly in 
the spleen, whereas it was markedly reduced following anti-Notch1 therapy. 
Indeed, PET images of anti-Notch1-treated mice were very similar to those of 
healthy mice (Fig. 11, middle panel). This result may either reflect decreased 
tumor burden as shown by other techniques or it could be explained by a 
metabolic changes, as highlighted by GEP analysis and 2-NBDG uptake reported 
hereafter.  
In figure 11 (bottom panel), macroscopic differences between spleens and femurs 
in ctrl Ab- and anti-Notch1-treated mice are shown. Splenomegaly was 
completely absent in anti-Notch1-treated mice. Moreover, femurs of treated 
animal had a reddish appearance contrasting with the pale femurs of control mice, 
which reflected massive infiltration and replacement of normal hematopoiesis by 
leukemia cells. 
 
 49 
 
 
 
 
Figure 11: Anti-Notch1 reduces tumor burden in mice bearing human T-ALL cells. Top: Optical 
imaging in PDTALL19 xenografts treated with control Ab or anti-Notch1. PDTALL19 cells were 
labeled with the luciferase gene and injected i.v. into NOD/SCID mice (5×106 cells/mouse; n=5 
mice/group). Images acquired at day 13, 15, 17 after cells injection of three representative ctrl Ab- 
or anti-Notch1 treated mice are reported. On the right, quantitative analysis of luciferase activity in 
vivo at the same time points of measurement (n=5 mice/group). Statistically significant differences 
in average radiance in the two groups of samples are indicated (**P<0.001).Middle: 
Representative images of [18F]FDG-PET analysis of control antibody- and anti-Notch1-treated 
PDTALL19 xenografts (n=5 mice/group). NOD/SCID mice without leukemia were used as control 
(n=3). Measurements of [18F]FDG uptake in the analyzed mice are reported in the graph, 
expressed as percentage of injected dose per gram of tissue (%ID/g). and statistically significant 
differences in the two groups of samples are indicated (*P<0.05). White arrows indicate highly 
glycolytic spleens. Bottom: Macroscopic features of spleen and femurs from ctrl Ab- or anti-
Notch1 treated mice. Leukemia outgrowth is accompanied by splenomegaly and pale appearance 
of BM, two pathologic features which are lacking in anti-Notch1 treated mice. 
 50 
 
Given such promising results, we investigated whether anti-Notch1 therapy was 
effective also in mice with advanced disease. In this setting, mice bearing about 
5% leukemia cells in the spleen and nearly 25% in the BM received 2 i.p. 
injections of anti-Notch1 mAb on day 11 and day 17 after cells injection (Fig. 12, 
top panel). Blood drawings showed that levels of circulating blasts increased in 
control mice whereas they remained stable in anti-Notch1-treated animals. At 
sacrifice, anti-Notch1-treated mice had significantly lower levels of leukemic cells 
in the spleen and BM (Fig. 12, bottom panel).  
 
 
 
Figure 12: Therapeutic effects of anti-Notch1 therapy in the advanced disease setting. Top: 
Outline of late intervention treatment with anti-Notch1 or control antibody (ctrl Ab) in PDTALL8 
xenografts (n=6 mice/group) (left panel). Treatment was started 11 days after i.v. injection of T-
ALL cells, when various levels of leukemia cells were detected in the blood, spleen and BM of the 
mice (right panel, n=3 mice). Bottom: Measurement of leukemia cells in the blood at different 
time points (left). Levels of T-ALL cells recovered in the spleen and BM at sacrifice and picture of 
the spleen in control and anti-Notch1-treated mice (right). Statistically significant differences in 
the two groups of samples are indicated (** P<0.001). 
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4.4 Analysis of the effects of anti-Notch1 mAb on gene expression 
To assess whether anti-leukemia effects were in fact due to blockade of Notch 
signaling, we measured levels of a set of Notch-target transcripts by 
TaqMan®Arrays. To this end, we sorted leukemic CD5+ cells from either spleen 
or BM of anti-Notch1-treated or control mice and extracted RNA from these 
pooled samples. Results showed that the therapeutic response was associated with 
a strong inhibition of Notch signaling, as depicted in figure 13. In particular four 
genes (CR2, DTX1, HES1 and HES4) emerged as markedly attenuated following 
treatment, suggesting them as sentinel genes of the therapeutic response. 
Interesting, similar results in terms of gene expression were obtained in mice 
receiving anti-Notch1 therapy as an early or a late therapeutic protocol.  
On the contrary, in poor responders several Notch-related transcripts were poorly 
expressed and their expression levels were minimally perturbed by anti-Notch1 
therapy. Among these genes, DTX1, HES4 and NOTCH3 were undetectable as 
opposed to high expression in good responders, fitting with their features of 
sentinel genes. The transcriptional profile of PDTALL13 following anti-Notch1 
therapy is reported in figure 13 and very similar results were obtained with 
PDTALL16, another poor-responder (data not shown). 
 
 
 
 
 
 
 52 
 
 
 
 
Figure 13: Anti-Notch1 therapy inhibits Notch signaling in T-ALL xenografts. Human CD5+ cells 
were sorted from spleen and BM of anti-Notch1 treated or control mice, pooled (n=3-6 samples 
per pool) and utilized to investigate effects on Notch signaling. Expression levels of 21 Notch-
target genes were measured using Low Density qRT-PCR Arrays. Top: Gene expression profile in 
PDTALL19 xenograft, a representative example of an anti-Notch1 good responder. Treatment - 
initiated at day 2 - was highly effective in inhibiting expression of Notch target genes both in 
spleen and in BM. Middle: Gene expression profile in PDTALL8 xenograft in the late 
intervention trial, in which therapy was started at day 11 Bottom:. Gene expression profile in 
PDTALL13, a xenograft which does not respond to anti-Notch1 therapy. 
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Since we observed such a clear distinction between the transcriptional profile of 
anti-Notch1 good and poor responders, we wondered if anti-Notch1 therapy could 
affected other cellular pathways and genes. With this concept in mind, we 
performed Affymetrix gene expression analysis from pools of PDTALL19 cells 
purified from the BM of mice treated with anti-Notch1 or control mAbs (3 
replicates). The global overview of the highly significantly modulated transcripts 
confirmed results obtained with TaqMan®Arrays, indicating a marked reduction in 
expression levels of several canonical Notch target genes such as CR2, DTX1, 
HES1 and NOTCH3 (Fig. 14).  
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Figure 14: Global changes in gene expression 
profile following anti-Notch1 therapy in 
leukemia-bearing mice. Here is reported the 
heat map of top 53 significant genes that turn 
out to be up- or down-regulated with BH 
adjusted p-value< 0.002. Hierarchical clustering 
of genes (rows) and samples (columns) is based 
on Euclidean distance metric and complete 
linkage method while color coding is used to 
represent absolute gene expression levels, the 
largest expression values are displayed in red 
(hot), the smallest values in blue (cool). 
Clustering on samples was also used as a 
preliminary quality control. Genes are grouped 
in two main clusters representing up- and 
down-regulated genes in antiNotch1 (aN1) vs. 
control antibody (ctrl Ab); two up-regulated 
genes (SMURF2 and RHOU) are clustering 
separately due to gene expression levels very 
different from the corresponding groups.  
 
 
 55 
 
Moreover, Affymetrix arrays disclosed that Notch1 blockade modulates 
expression of several transcripts involved in metabolic functions, such as 
glycolysis-associated genes (PFKFB2, ALDOC), membrane carriers (SLC29A1, 
SLC16A6), and channels (CLCA1, SCN3A) (Fig. 14). Intrigued by these data, we 
performed a preliminary experiment in which we detected the uptake of a 
fluorescent glucose analog (2-NBDG) in PDTALL8-bearing mice treated with 
control Ab or anti-Notch1. As shown in figure 15, T-ALL cells recovered from 
anti-Notch1-treated mice captured less 2-NBDG compared to control Ab-treated 
mice both in spleen and BM. These preliminary findings fit with the well-
established activity of Notch signaling on cellular metabolism (Palomero et al., 
2006). 
 
 
Figure 15: Anti-Notch1 therapy decreases glucose uptake. Left: Measurements of 2-NBDG 
uptake by T-ALL cells in spleen and BM of mice treated with control or anti-Notch1 Abs. (*: 
p=0.002). Right: One representative example of flow cytometric analysis of glucose uptake in 
spleen and BM. [2-NBDG = 2-N-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose] 
 
Gene set enrichment analysis (GSEA) highlighted that the most relevant effects of 
anti-Notch1 on coordinated groups of genes were mainly in the sense of down-
regulation, specifically 36 up- and 374 down-regulated gene sets were identified 
(false discovery rate FDR q-value < 0.05). Interestingly, among the top list of 
down-regulated gene sets we noticed several gene sets representing MYC targets, 
confirming the role of MYC as important mediator of Notch1 activity (Palomero 
et al., 2006; Sharma et al., 2006; Weng et al., 2006). Restricting our attention to 
KEGG pathways, we identified 22 significantly down-regulated pathways (Table 
III) and no significant up-regulated pathways with FDR q-value < 0.05. Moreover, 
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GSEA was used to evaluate the significance of sets of genes, grouped together by 
biological process as defined in the Gene Ontology. The analysis disclosed 12 
biological process significantly down-regulated, reported in Table III. 
 
# Name of KEGG pathway significantly down-regulated SIZE NES FDR q-val
1 DNA_REPLICATION 32 -2,29 0,0011
2 PROTEASOME 36 -2,27 0,0006
3 PURINE_METABOLISM 102 -2,19 0,0004
4 PYRIMIDINE_METABOLISM 73 -2,09 0,0021
5 NOTCH_SIGNALING_PATHWAY 36 -2,07 0,0031
6 COMPLEMENT_AND_COAGULATION_CASCADES 19 -2,01 0,0060
7 GLUTATHIONE_METABOLISM 31 -1,99 0,0055
8 CELL_CYCLE 98 -1,93 0,0081
9 AMINOACYL_TRNA_BIOSYNTHESIS 38 -1,88 0,0124
10 HOMOLOGOUS_RECOMBINATION 21 -1,84 0,0169
11 BASE_EXCISION_REPAIR 27 -1,81 0,0194
12 PYRUVATE_METABOLISM 30 -1,80 0,0205
13 CYSTEINE_AND_METHIONINE_METABOLISM 23 -1,80 0,0201
14 RIBOSOME 49 -1,77 0,0234
15 RNA_POLYMERASE 24 -1,77 0,0220
16 ARGININE_AND_PROLINE_METABOLISM 24 -1,75 0,0266
17 NUCLEOTIDE_EXCISION_REPAIR 37 -1,73 0,0293
18 MISMATCH_REPAIR 21 -1,73 0,0281
19 DRUG_METABOLISM_OTHER_ENZYMES 15 -1,72 0,0295
20 AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 30 -1,70 0,0341
21 GLYCINE_SERINE_AND_THREONINE_METABOLISM 21 -1,66 0,0469
22 HEMATOPOIETIC_CELL_LINEAGE 45 -1,64 0,0496
# GO biological process significantly down-regulated SIZE NES FDR q-val
1 DNA_DEPENDENT_DNA_REPLICATION 42 -2,09 0,0095
2 PROTEIN_FOLDING 46 -2,11 0,0124
3 DNA_REPLICATION 77 -2,04 0,0138
4 DNA_DAMAGE_RESPONSE SIGNAL_TRANSDUCTION 21 -1,95 0,0223
5 TRNA_METABOLIC_PROCESS 16 -1,98 0,0231
6 NUCLEO BASE NUCLEOSIDE_AND_NUCLEOTIDE_METABOLIC_PROCESS 37 -1,95 0,0252
7 M_PHASE 80 -1,89 0,0253
8 CELLULAR_BIOSYNTHETIC_PROCESS 202 -1,89 0,0256
9 CELL_CYCLE_PROCESS 135 -1,89 0,0270
10 CELL_CYCLE_PHASE 120 -1,90 0,0277
11 DNA_METABOLIC_PROCESS 192 -1,91 0,0295
12 NUCLEOTIDE_METABOLIC_PROCESS 28 -1,91 0,0322
 
Table III: GSEA results applied to KEGG pathways and to GO biological process gene sets 
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4.5 Analysis of the effects of anti-Notch1 mAb on leukemia-
initiating cells 
In the last years, different groups have studied various subsets of leukemic cells in 
order to identify leukemia initiating cells (L-IC) that may account for disease 
progression. Regarding T-ALL, previous studies disclosed that CD34+CD4-CD7- 
cells might be enriched in L-IC (Cox et al., 2007). However, other groups 
reported that the CD34+CD7+ (Gerby et al., 2011) or the CD7+CD1a- (Chiu et al., 
2010) subsets might contain L-IC. We analyzed expression of these markers by 
flow cytometry but CD34+CD4-CD7- and CD34+CD7+ were almost undetectable 
(<0.1%) in PDTALL8 and PDTALL19 xenografts and their number did not 
change following treatment. Since these analysis were low informative, we 
investigated whether efficacy of anti-Notch1 therapy was associated with 
reduction of tumorigenic potential by serial transplantation experiments. 
PDTALL19-bearing mice were treated according to standard early treatment 
outline. At sacrifice, viable T-ALL cells were FACS sorted from spleen of control 
Ab- or anti-Notch1-treated mice and injected at 3 different doses (1x105, 2.5x104, 
6.25x103 cells) into naïve NOD/SCID mice (4 mice per group). Recipient mice 
were not treated and leukemia engraftment was periodically monitored by blood 
drawings. Mice injected with T-ALL cells from control Ab-treated mice 
developed full blown leukemia in 27-34 days, depending on the cell dose 
received. In contrast, in all mice injected with cells obtained from anti-Notch1-
treated animals very low percentages of leukemic cells were recovered in the 
blood and mice seemed healthy. These mice eventually developed leukemia, 10-
12 days after the sacrifice of control mice (Fig. 16, top panel). These results 
suggest that anti-Notch1 therapy reduces leukemia engraftment during the 
treatment and furthermore impairs the ability of T-ALL cells to re-grow after 
serial transplantation.  
Finally we investigated whether leukemia arising in mice injected with cells from 
anti-Notch1 treated mice were still responder to anti-Notch1 therapy. These cells 
were hence injected in naïve mice and were treated with anti-Notch1 or control 
Ab according to standard protocol. Therapeutic response was comparable to those 
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measured in previous experiments, suggesting that these cells were still sensitive 
to anti-Notch1 therapy (Fig 16, bottom panel). 
 
 
 
Figure 16: Anti-Notch1 therapy delays T-ALL engraftment. Top: Percentages of circulating 
blasts at different time points in mice injected with serial (1:4) dilutions of human CD5+ cells 
(1x105, 2.5x104, 6.25x103 cells/mouse) sorted from the spleen of ctrl Ab and anti-Notch1 treated 
mice (n=4 mice/group). Bottom: Leukemia cells obtained at sacrifice (day 46) from the spleen of 
mice injected with T-ALL cells from anti-Notch1-treated mice were injected in naive NOD/SCID 
mice (n=5 mice/group), and two days later these mice were treated with weekly injections of ctrl 
Ab or anti-Notch1 antibodies. Measurements of circulating blasts are reported in the left panel 
while percentages of blasts and apoptotic cells at sacrifice are represented in middle and right 
panel respectively. Statistically significant differences are indicated (** P<0.001). 
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4.6 Resistance to Notch1-targeted therapy: preliminary data 
Xenografts with NOTCH1 mutations respond well to anti-Notch1 therapy, but are 
these responses sustained? Do T-ALL cells become resistant to anti-Notch1 
therapy? Intrigued by this question, we treated PDTALL19-bearing mice with 
anti-Notch1 antibody until progression. T-ALL cells engraftment in mice were 
monitored both by flow cytometric analysis of blood drawings and 
bioluminescence imaging. 17 days after cells injection, control Ab-treated mice 
were sacrificed because of widespread leukemia and signs of illness whereas anti-
Notch1-treated mice had very low levels of circulating blasts (Fig. 17). However, 
blood drawings carried out at subsequent time points disclosed growing levels of 
leukemic cells. Interestingly, even though the percentages of leukemic cells 
gradually increased, the reduction in the surface CD7 expression was maintained 
for the entire experiment. Anti-Notch1-treated mice were sacrificed after 6 
injections of anti-Notch1 antibody at day 44, that is an increase in the overall 
survival of 27 days compared to control Ab-treated mice. According to our 
experience PDTALL19 are very aggressive xenografts, causing leukemia within 
14-17 days if injected at ordinary dose (5x106 cells in experiments). Considering 
this aspect, an increase in the overall survival of nearly one month can be 
interpreted as a rather good outcome. We will further investigate the 
mechanism(s) at the base of resistance, in order to discern whether resistance to 
Notch1 neutralization could be due to escape mechanisms involving the target 
(i.e. mutations in the epitope bound by the therapeutic antibody) or selection of T-
ALL clones driven by other Notch-unrelated pathways and finally clarify if 
resistance to anti-Notch1 therapy is a stable trait. 
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Figure 17: Optical imaging in PDTALL19 xenograft disclosed onset of resistance to Notch1-
targeted therapy. PDTALL19 cells were labeled with the luciferase gene and injected i.v. into 
NOD/SCID mice (5×106 cells/mouse; n=5 mice/group). Top: The last imaging performed in ctrl 
Ab-treated mice on day 17, immediately before sacrifice (three representative mice). Bottom: 
Images of three representative anti-Notch1 treated mice captured at different time points (day 17, 
27, 37 and 43 after cells injection). On the right, quantitative analysis of luciferase activity in vivo 
at the same time points of measurement in anti-Notch1-treated mice (n=5 mice). 
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During preparation of this thesis, the same experiment was repeated with 
PDTALL12 cells, which were even better responder to anti-Notch1 therapy 
compared to PDTALL19 cells. Control Ab-treated mice were sacrificed 16 days 
after cells injection, whereas anti-Notch1-treated mice did not present signs of 
leukemia up to >75 days later.  
 
4.7 Preliminary experiments about combination of anti-Notch1 
mAb and dexamethasone 
Our previous results indicate that anti-Notch1 therapy reduces but does not 
completely block leukemia engraftment or L-IC function, furthermore resistance 
may arise in a regimen of continuous administration of anti-Notch1 mAb. 
Combination of drugs might putatively improve therapeutic efficacy, by further 
reducing leukemia cell burden. In a preliminary experiment, we treated PDTALL8 
xenografts either with dexamethasone -a drug commonly used for T-ALL 
treatment- combined or not with anti-Notch1 (5 mice/group). Anti-Notch1 was 
administered 11 days after cells injection, as in the late intervention trial, in order 
to decrease but not totally eliminate leukemia cell engraftment. This residual 
disease could be further reduced by administration of dexamethasone. Leukemia 
engraftment was monitored by blood drawings and percentages of blasts and 
apoptotic cells in spleen and BM were measured at sacrifice. As represented in 
figure 18, levels of leukemic cells in mice treated with the combination of both 
drugs were extremely low. Moreover, apoptosis of T-ALL cells was significantly 
higher in the group receiving the combination of anti-Notch1 and dexamethasone 
in respect to groups treated with single therapies both in the spleen and in the BM. 
These findings were further confirmed by comparing weight of the spleen from 
the various animals (data not shown). This preliminary experiment suggests a 
potential synergistic effect of anti-Notch1 and dexamethasone treatments, a 
promising result for future therapeutic applications of anti-Notch1 therapy for T-
ALL.  
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Fig. 18: Combination of dexamethasone and anti-Notch1 mAb impairs leukemia cell engraftment. 
Top: measurements of circulating blasts in mice treated with either control Ab, anti-Notch1, 
dexamethasone or a combination of both reagents. Bottom: Evaluation of leukemic cells in spleen 
and BM in mice that received one of the treatment reported in the legend. The combination of 
dexamethasone and anti-Notch1 has stronger therapeutic effect compared to monotherapy. 
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5. DISCUSSION 
 
Although we are aware of intrinsic limitations of xenografts, the systemic T-ALL 
model generated in our lab was very useful to investigate the therapeutic activity 
of a novel neutralizing antibody against Notch1. Earlier studies about Notch-
targeted therapies were limited to T-ALL cell lines in vitro (Aste-Amezaga et al., 
2010) or grown in vivo as s.c. tumor xenografts (Wu et al., 2010), a model barely 
suitable for an hematological disease such as T-ALL. Only a very recent study 
(Ma et al., 2012) analyzed the effects of another Notch1-specific antibody in a 
systemic xenograft model of T-ALL. However, this group mainly focused L-IC 
subpopulations, demonstrating that Notch1-targeted therapy resulted in substantial 
depletion of CD34+CD2+CD7+ cells, and did not investigate mechanisms behind 
the therapeutic effects and possible predictive biomarkers. On the other hand, 
xenografts that responded to anti-Notch1 therapy in our study had negligible 
levels of CD34+ cells, therefore it was not possible to validate the findings of Ma 
and colleagues in our model.  
Our clinically relevant T-ALL model permitted us to study the therapeutic effects 
of Notch1 blockade in xenografts derived from difficult-to-treat patients, as 
PDTALL19, which was derived from a relapse, or poor responders to prednisone 
(PDTALL8, PDTALL11, PDTALL16, PDTALL18, PDTALL19). Anti-Notch1 
therapy was effective in several of these xenografts, an encouraging result 
considering the lack of efficacy of established therapies for poor prognosis T-ALL 
patients (Coustan-Smith et al., 2009; Zhang et al., 2012). Our results demonstrated 
that NOTCH1/FBW7 mutated samples are suitable candidates for Notch1-targeted 
therapy, since all mutation-bearing xenografts analyzed presented a significant 
reduction in leukemia engraftment, increased apoptosis levels and a decrease in 
cell proliferation compared to control mice. Therapeutic efficacy was detected 
even in the late intervention trial, notwithstanding an involvement of near 25% of 
BM by leukemia cells at time of drug administration. Differences in apoptosis and 
proliferation following Notch1 blockade are in line with literature findings with 
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GSI (Lewis et al., 2007; Weng et al., 2004). Efficacy of anti-Notch1 therapy 
seemed to be rather independent from the specific mutation, considering that we 
tested mutations in HD domain (PDTALL11), in PEST (PDTALL12), in 
HD/PEST (PDTALL8) and HD/TAD plus mutation in FBW7 (PDTALL19) and 
all were good responders according to results explained above. On the contrary, 
xenografts with wild-type NOTCH1 and FBW7 sequences did not respond to anti-
Notch1 treatment. Altogether, our findings clearly demonstrate that 
NOTCH1/FBW7 mutations identify responders in xenografts. In future studies, 
genetic screening could be helpful to stratify patients and identify predictive 
biomarkers of response to this targeted therapy. 
A very interesting result that emerges from our findings is the correlation between 
the mutational status, the response to anti-Notch1 therapy and the expression of 
some Notch target genes such as DTX1, HES4 and NOTCH3. These genes were 
absent or undetectable in wt/poor responder xenografts whereas they were highly 
expressed, and modulated following therapy, in mutated/good responder 
xenografts, suggesting them as sentinel genes for the therapeutic response. 
Moreover the efficacy of anti-Notch1 therapy correlated also with surface 
expression of CD7, since its down-modulation was a stable trait in all responder 
samples and was confirmed also at transcriptional level by GEP analysis. These 
data highlight the potential of measurements of Notch target genes and/or CD7 
expression as candidate predictive markers of response to anti-Notch1 therapy. 
CD7 is one of the galectin-1 receptors and is directly regulated by NFκB upon T-
cell activation (Koh et al., 2008). It is known that NFκB activation is sustained by 
Notch pathway and in particular by HES1 (Espinosa et al., 2010), one of the most 
important Notch target genes. One hypothesis about down-modulation of CD7 
could be the decrease in CD7 expression due to reduced NFκB activity caused in 
turn by Notch1 blockade. Another possible explanation is that anti-Notch1 
treatment could impair growth of CD7+ cells, although cytofluorimetric data do 
not suggest the existence of distinct CD7 bright and dim cell populations in the 
samples.  
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Since Notch1 is expressed by leukemia cells, we planned to investigate the in 
vitro effects of anti-Notch1 antibody in order to further clarify the mechanism of 
the therapeutic effect. Unfortunately, the primary T-ALL cells derived from 
xenografts stop growing and tend to die quite rapidly in vitro, thus preventing the 
possibility of performing these experiments. 
The experiment with PDTALL19 xenograft disclosed that resistance may arise 
following prolonged anti-Notch1 therapy. Our systemic T-ALL model can also be 
utilized to investigate mechanisms of acquired resistance to Notch1-targeted 
therapy. We are indeed interested in understanding whether there is selection of a 
Notch-independent population sustained by other signaling pathways or if the 
escape mechanism involves the target (i.e. mutations in the epitope bound by the 
therapeutic antibody). Moreover, it will be important to investigate whether 
resistance is a stable trait or if T-ALL cells can still respond to anti-Notch1 
therapy upon serial transplantation in naive mice. Based on literature studies, 
some mutations, such as FBW7 or PTEN loss of function, correlate with resistance 
to GSI treatment in vitro (O'Neil et al., 2007; Palomero et al., 2007), so it will be 
important to check this possibility in our xenografts. Probably the finding of 
mutated FBW7 in PDTALL19 cells -which developed resistance to Notch 
inhibition- and wild-type FBW7 in PDTALL12 cells –which are still sensitive to 
Notch inhibition- is not a coincidence.  
Besides possible therapeutic implications, our study might be useful to improve 
knowledge about Notch signaling and its downstream pathways and genes. 
Results obtained by transcriptome analysis following Notch1 blockade disclosed 
the involvement of different genes of metabolic functions. It is known from the 
literature that Notch1 directly regulates c-MYC through a feed-forward-loop 
(Palomero et al., 2006) so it was not surprising to observed a modulation of the 
expression of c-MYC transcripts following anti-Notch1 therapy in our 
experiments. Moreover, a preliminary experiment suggested that anti-Notch1 
therapy compromised glucose uptake by leukemic cells, laying the foundations for 
future developments about anti-Notch1-mediated effect on cellular metabolism in 
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our model. Even PET analysis displayed a reduction in the [18F]FDG uptake in 
anti-Notch1-treated animals compare to control mice, but this result could be also 
explained by lower numbers of T-ALL cells infiltrating mouse organs, as shown 
by other techniques. 
Anti-Notch1 therapy reduced but did not completely block leukemia engraftment 
or L-IC function and residual cells maintained the potential to generate leukemia 
following serial transplantation (Fig. 16). Furthermore, resistance may arise in a 
regimen of continuous administration, as disclosed by the experiment with 
PDTALL19 cells. Therefore anti-Notch1 therapy alone may be not sufficient to 
achieve leukemia regression and therapeutic efficacy could be further improved 
by combination with steroids and other conventional drugs. In a preliminary 
experiment we combined the administration of anti-Notch1 with dexamethasone 
and the results were very encouraging, suggesting a cooperation between the 
novel antibody and the drug commonly administrated to T-ALL patients (Fig. 18). 
Findings are in line with recent evidences that Notch inhibition by GSI increased 
sensitivity to dexamethasone in T-ALL cells (Real et al., 2009). It should be noted 
that our antibody is specific only for Notch1 receptor, so its therapeutic 
application should overcome the severe toxicity associated with GSI 
administration, due to simultaneous blockade of all Notch receptors (Riccio et al., 
2008). In future we will implement our studies on combination of anti-Notch1 and 
other drugs by extending analysis to other xenografts. If the synergistic effect of 
anti-Notch1 and dexamethasone therapies will be confirmed, results will 
implement design of future clinical trials.  
Finally anti-Notch1 therapy could be extended also to other pathologic conditions 
where inhibition of Notch signaling is required, such as chronic lymphocytic 
leukemia (Fabbri et al., 2011) and mantle cell lymphoma (Kridel et al., 2012), 
hematological diseases in which activating mutations in NOTCH1 are frequent 
and are associated with poor clinical prognosis. 
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